Please find attached the Audited Financial Results for the quarter and financial year ended on March 31, 2026
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.9 pts more than Nifty Microcap 250 and 1.4 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Thyrocare Technologies reported strong full-year results with standalone revenue growing 22.3% to Rs 774.27 Crore and consolidated revenue up 20.6% to Rs 829.04 Crore versus the previous year. Standalone profit after tax jumped 55.4% to Rs 148.81 Crore, while consolidated PAT surged 79.5% to Rs 162.86 Crore. The company recognized Rs 5.97 Crore in exceptional items comprising Rs 4.01 Crore related to new Indian labour codes implementation and Rs 1.96 Crore in restructuring costs. Q4 standalone revenue was Rs 210.67 Crore with PAT of Rs 43.58 Crore. Statutory auditors M S K A & Associates issued an unmodified (clean) opinion on both standalone and consolidated financials. The Board recommended a final dividend of Rs 7 per equity share.
The results indicate robust operational performance with strong double-digit revenue growth and even sharper profit growth, suggesting improved operational efficiency. The clean audit opinion removes any concerns about financial reporting quality, and the recommended dividend signals management confidence. Shareholders can expect a positive market reaction given the healthy growth metrics.